Quality of life for patients treated for head and neck carcinoma;Qualité de vie chez les patients traités pour un cancer de la sphère ORL

Cancer/Radiotherapie

Volumn 14, Issue 6-7, 2010, Pages 526-529

  Maingon, P ^a   Crehange G ^a   Bonnetain, F ^a   Ligey Bartolomeu, A ^a   Chamois, J ^a   Bruchon, Y ^a   Romanet, P ^b   Truc, G ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Evaluation; Head and neck; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL; GOLD STANDARD; HEAD AND NECK CARCINOMA; HEALTH CARE UTILIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; LARYNX SURGERY; NASOPHARYNX CANCER; ODYNOPHAGIA; ORGAN PRESERVATION; OROPHARYNX CANCER; PATIENT SATISFACTION; PHYSICIAN; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION ONCOLOGIST; RISK ASSESSMENT; SALIVARY GLAND; SELF EVALUATION; SHORT SURVEY; SYMPTOM; TREATMENT INDICATION; XEROSTOMIA; CARCINOMA, SQUAMOUS CELL; DEGLUTITION DISORDERS; HEAD AND NECK NEOPLASMS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PHARYNGEAL MUSCLE; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; PSYCHOLOGY; RADIATION INJURIES; RADIATION RESPONSE; SEVERITY OF ILLNESS INDEX; STOMATITIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; HEAD AND NECK NEOPLASMS; HUMANS; MULTICENTER STUDIES AS TOPIC; PATIENT SATISFACTION; PHARYNGEAL MUSCLES; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY, INTENSITY-MODULATED; SALIVARY GLANDS; SEVERITY OF ILLNESS INDEX; STOMATITIS; XEROSTOMIA;

EID: 77957288700     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.06.008     Document Type: Short Survey

References (17)

1. Beitz J., Gnecco C., Justice R. Quality-of-life end points in cancer clinical trials: the US food and drug administration perspective. J Natl Cancer Inst Monogr 1996, 20:7-9.
2. Carr A.J., Gibson B., Robinson P.G. Measuring quality of life: is quality of life determined by expectations or experience?. BMJ 2001, 322:1240-1243.
3. Demez P.H., Moreau P.R. Perception of head and neck cancer quality of life within the medical world: a multicultural study. Head Neck 2009, 31:1056-1067.
4. Eisbruch A. Reducing xerostomia by IMRT: what may, and may not, be achieved. J Clin Oncol 2007, 25:4863-4864.
5. Elting L.S., Keefe D.M., Sonis S.T., Garden A.S., Spijkervet F.K., Barasch A., et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 2008, 113:2704-2713.
6. Fairclough D. Design and analysis of quality of life studies in clinical trials. Boca Raton: Chapman and Hall/CRC; 2002.
7. Graff P., Lapeyre M., Desandes E., Ortholan C., Bensadoun R.J., Alfonsi M., et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67:1309-1317.
8. Jabbari S., Kim H.M., Feng M., Lin A., Tsien C., Elshaikh M., et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys 2005, 63:725-731.
9. Johnson J.R., Temple R. Food and drug administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985, 69:1155-1159.
10. Karvonen-Gutierrez C.A., Ronis D.L., Fowler K.E., Terrell J.E., Gruber S.B., Duffy S.A. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol 2008, 26:2754-2760.
11. Konski A.A., Winter K., Cole B.F., Ang K.K., Fu K.K. Quality-adjusted survival analysis of radiation therapy oncology group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. Head Neck 2009, 31:207-212.
12. Langendijk J.A., Doornaert P., Verdonck-de L., Leemans C.R.I., Aaronson N.K., Slotman B.J. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008, 26:3770-3776.
13. Lefebvre J.L., Ang K.K. Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Int J Radiat Oncol Biol Phys 2009, 73:1293-1303.
14. Levendag P.C., Teguh D.N., Voet P., van Der E.H., Noever I., de Kruijf W.J., et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 2007, 85:64-73.
15. Osoba D., Zee B., Pater J., Warr D., Kaizer L., Latreille J. Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994, 3:353-364.
16. Pow E.H., Kwong D.L., McMillan A.S., Wong M.C., Sham J.S., Leung L.H., et al. Xerostomia and quality of life after intensity-modulated radiotherapy versus conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66:981-991.
17. Wood-Dauphinee S. Assessing quality of life in clinical research: from where have we come and where are we going?. J Clin Epidemiol 1999, 52:355-363.